However, adverse musculoskeletal effects make them intolerable for some patients.

然而，肌肉骨骼的不良影響使一些患者無法忍受。

A recent trial examined the efficacy and safety of bempedoic acid, an ATP citrate lyase inhibitor, that reduces LDL cholesterol, for preventing cardiovascular events in patients with statin intolerance.

最近的一項試驗研究了貝門冬氨酸的有效性和安全性，貝門冬氨酸是一種 ATP 檸檬酸酶抑制劑，可降低低密度脂蛋白膽固醇，用於預防他汀類藥物不耐受患者的心血管事件。

In this double-blind, randomized, placebo-controlled trial, 13,970 patients 18 to 85 years of age with increased cardiovascular risk, who were unable or unwilling to take guideline-recommended doses of statins, were assigned to receive 180 mg of oral bempedoic acid, or placebo, daily.

在這項雙盲、隨機、安慰劑對照試驗中，13970 名年齡在 18 至 85 歲之間、心血管風險較高、無法或不願服用指導建議劑量他汀類藥物的患者被分配到每天口服 180 毫克貝母魚子酸或安慰劑。

After a median follow-up of 40.6 months, the incidence of a primary endpoint event, a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, was significantly lower in the bempedoic acid group, at 11.7%, than in the placebo group, at 13.3%.

在中位隨訪 40.6 個月後，主要終點事件（心血管原因導致的死亡、非致命性心肌梗死、非致命性中風或冠狀動脈血運重建的綜合結果）的發生率在魚貝多酸組（11.7%）顯著低於安慰劑組（13.3%）。

A key secondary efficacy endpoint event, a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurred significantly less often in the bempedoic acid group.

一個關鍵的次要療效終點事件，即心血管原因導致的死亡、非致命性心肌梗死或非致命性中風的複合事件，在貝母雙酸組發生的頻率明顯降低。

The overall rate of adverse events was similar in the two groups.

兩組的不良反應總髮生率相似。

However, the bempedoic acid group had higher frequencies of elevated hepatic enzymes, renal impairment, hyperuricemia, gout, and cholelithiasis.

不過，貝母多酸組出現肝酶升高、腎功能損害、高尿酸血癥、痛風和膽石症的頻率較高。

The authors conclude that in statin-intolerant patients requiring therapy for primary or secondary prevention of cardiovascular disease, treatment with bempedoic acid during a median follow-up of 40.6 months significantly reduced the risk of major adverse cardiovascular events.

作者總結說，對於不耐受他汀類藥物、需要接受心血管疾病一級或二級預防治療的患者，在中位 40.6 個月的隨訪期間使用貝母多酸治療可顯著降低主要不良心血管事件的風險。

Full trial results are available at NEJM.org.

試驗結果全文可在 NEJM.org 上查閱。

For more information visit www.nejm.org

欲瞭解更多資訊，請訪問 www.nejm.org